A5037668056- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Functional Brain Connectivity Studies
- Medical Imaging Techniques and Applications
- Advanced Neuroimaging Techniques and Applications
- S100 Proteins and Annexins
- Neuroinflammation and Neurodegeneration Mechanisms
- Lanthanide and Transition Metal Complexes
- Advanced MRI Techniques and Applications
- Neuroscience and Neuropharmacology Research
- Radiopharmaceutical Chemistry and Applications
- Neurological Disease Mechanisms and Treatments
- Neural dynamics and brain function
- Inflammation biomarkers and pathways
- Epilepsy research and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Cholinesterase and Neurodegenerative Diseases
- Medical Image Segmentation Techniques
- Visual Attention and Saliency Detection
- Tryptophan and brain disorders
- Long-Term Effects of COVID-19
- Traumatic Brain Injury and Neurovascular Disturbances
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Genetic Neurodegenerative Diseases
- Neurological and metabolic disorders
Amsterdam Neuroscience
2019-2025
Amsterdam UMC Location Vrije Universiteit Amsterdam
2024-2025
Amsterdam University Medical Centers
2019-2024
Vrije Universiteit Amsterdam
2019-2024
University of Amsterdam
2019-2023
Lund University
2023
Portal (Norway)
2023
Portál (Czechia)
2023
The mechanism of synaptic loss in Alzheimer's disease is poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) magnetoencephalography (MEG) study, we aimed to investigate spatial associations between regional pathology ([18F]flortaucipir PET), density (synaptic vesicle 2A [11C]UCB-J PET) function disease.Seven amyloid-positive subjects from the Amsterdam Dementia Cohort underwent dynamic 130-min [18F]flortaucipir PET, 60-min PET...
Gitelman9s syndrome is a congenital renal tubular defect which affects the apical membrane of distal convoluted tubule system. The characterised by hypokalaemia, hypomagnesaemia, metabolic alkalosis and hypocalcuria. There are only few cases describing impact on pregnancy foetus. Although most pregnancies have favourable outcomes, fetal demise has been reported in third trimester. We report successful outcome patient with who continued amiloride to optimise potassium magnesium levels review...
Recent studies on Alzheimer's disease (AD) suggest that tau proteins spread through the brain following neuronal connections. Several mechanisms could be involved in this process: spreading between regions interact strongly (functional connectivity); pattern of anatomical connections (structural or simple diffusion. Using magnetoencephalography (MEG), we investigated which pathways influence protein by modelling propagation process using an epidemic model. We compared modelled depositions...
Abstract Cerebrovascular pathology often co-exists with Alzheimer’s disease and can contribute to disease-related clinical progression. However, the degree which vascular burden contributes pathological progression is still unclear. This study aimed investigate interactions between amyloid-β on both baseline tau tangle load longitudinal accumulation. We included 1229 participants from Swedish BioFINDER-2 Study, including cognitively unimpaired impaired without biomarker-confirmed pathology....
Summary A significant number of COVID-19 patients develop ‘long COVID’, a condition defined by long-lasting debilitating, often neurological, symptoms. The pathophysiology long COVID is unknown. Here we present in-vivo evidence widespread neuroinflammation in COVID, using quantitative assessment, [ 18 F]DPA-714 PET, two patients. We reanalyzed historical data from three matched healthy control subjects, for comparison purposes. Both with had increases binding throughout the brain....
Rare variants of the triggering receptor expressed on myeloid cell 2 (TREM2) gene are strong risk factors for Alzheimer's disease (AD), and drugs targeting TREM2 protein being developed. However, it is unknown what effect AD phenotype. Here we studied a full range clinical biomarker measures in large cohort variant carriers (n = 123, 7.8%, i.e., R62H n 66, R47H 26, T96K 16, other 17) compared to confirmed non-carriers 1,459) with symptomatic from Amsterdam Dementia Cohort. Secondly, explored...
Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer's disease (AD), but their relative performance predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. In a head-to-head comparison study including nine cohorts 1,474 individuals, we show that plasma medial temporal lobe tau-PET signal display similar associations with on global composite test (R2PET = 0.34 versus R2plasma 0.33, Pdifference 0.653)...
Abstract Purpose We aimed to investigate associations between tau pathology and relative cerebral blood flow (rCBF), their relationship with cognition in Alzheimer’s disease (AD), by using a single dynamic [ 18 F]flortaucipir positron emission tomography (PET) scan. Methods Seventy-one subjects AD (66 ± 8 years, mini-mental state examination (MMSE) 23 4) underwent 130-min PET Cognitive assessment consisted of composite scores four cognitive domains. For rCBF, receptor parametric mapping...
Abstract Purpose In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated (p-tau) and [ 18 F]flortaucipir positron emission tomography (PET). Our aim was to assess associations between CSF p-tau with PET the of both cognition atrophy. Methods We included 78 amyloid positive cognitively impaired patients (clinical diagnoses mild cognitive impairment (MCI, n = 8) AD dementia ( 45) 25 normal subjects subjective decline (SCD) (40%...
Recently, the US Food and Drug Administration approved tau-binding radiotracer [
Objective The clinical phenotype of the rare behavioural variant Alzheimer’s disease (bvAD) is insufficiently understood. Given strong clinico-anatomical correlations tau pathology in AD, we investigated distribution deposits bvAD, in-vivo and ex-vivo, using positron emission tomography (PET) postmortem examination. Methods For PET study, seven amyloid-β positive bvAD patients underwent [ 18 F]flortaucipir or F]RO948 PET. We converted uptake values into standardised (W-)scores, adjusting for...
Tau accumulation starts during the preclinical phase of Alzheimer's disease and is closely associated with cognitive decline. For preventive purposes, it important to identify factors tau spread. Studying genetically identical twin-pairs may give insight into genetic environmental contributions pathology, as similarities in largely result from factors, while differences can be attributed non-shared, factors. This study aimed examine dissimilarities a cohort older (i) load; (ii) spatial...
[ 11 C]UCB-J is a novel radioligand that binds to synaptic vesicle glycoprotein 2A (SV2A). The main objective of this study was determine the 28-day test–retest repeatability (TRT) quantitative brain positron emission tomography (PET) imaging in Alzheimer’s disease (AD) patients and healthy controls (HCs). Nine HCs eight AD underwent two 60 min dynamic PET scans with arterial sampling an interval 28 days. optimal tracer kinetic model assessed using Akaike criteria (AIC)....
Early-onset Alzheimer's disease (EOAD) and late-onset (LOAD) differ in neuropathological burden type of cognitive deficits. Assessing tau pathology relative cerebral blood flow (rCBF) measured with [18F]flortaucipir PET relation to cognition may help explain these differences between EOAD LOAD.Seventy-nine amyloid-positive individuals a clinical diagnosis AD (EOAD: n = 35, age-at-PET 59 ± 5, MMSE 23 4; LOAD: 44, 71 4) underwent 130-min dynamic scan extensive neuropsychological assessment. We...
Abstract The amyloid cascade hypothesis has strongly impacted the Alzheimer's disease research agenda and clinical trial designs over past decades, but precisely how amyloid-β pathology initiates aggregation of neocortical tau remains unclear. We cannot exclude possibility a shared upstream process driving both in an independent manner instead there being causal relationship between tau. Here, we tested premise that if exists, then exposure should be associated with outcome at individual...
Plasma p-tau217 and Tau-PET are strong prognostic biomarkers in Alzheimer's disease (AD), but their relative performance predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. In this head-to-head comparison study including 9 cohorts 1534 individuals, we found that plasma medial temporal lobe signal showed similar associations with on a global composite test (R
Alpha-synuclein often co-occurs with Alzheimer's disease (AD) pathology in Dementia Lewy Bodies (DLB). From a dynamic [18F]flortaucipir PET scan we derived measures of both tau binding and relative cerebral blood flow (rCBF). We tested whether regional or rCBF differed between DLB patients AD controls examined their association clinical characteristics DLB. Eighteen probable DLB, 65 50 underwent 130-minute scan. positive biomarkers for based on cerebrospinal fluid amyloid were considered as...
Aging-related cognitive decline can be accelerated by a combination of genetic factors, cardiovascular and cerebrovascular dysfunction, amyloid-β burden. Whereas cerebral blood flow (CBF) has been studied as potential early biomarker decline, its normal variability in healthy elderly is less known. In this study, we investigated the contribution genetic, vascular, components CBF cognitively unimpaired (CU) population monozygotic older twins. We included 134 participants who underwent...
Introduction The risk factors for persistent fatigue and cognitive complaints after infection with SARS-CoV-2 the underlying pathophysiology are largely unknown. Both clinical cognitive-behavioural have been suggested to play a role in perpetuation of complaints. A neurobiological aetiology, such as neuroinflammation, could be pathophysiological mechanism persisting To unravel associated complaints, VeCosCO will compare individuals without >3 months SARS-CoV-2. study consists two work...
Abstract [ 11 C]UCB-J is a PET radioligand that binds to the presynaptic vesicle glycoprotein 2A. Therefore, may serve as an in vivo marker of synaptic integrity. The main objective this study was evaluate quantitative accuracy and 28-day test–retest repeatability (TRT) various parametric methods for dynamic studies Alzheimer’s disease (AD) patients healthy controls (HC). Eight HCs seven AD underwent two 60-min scans with arterial sampling over interval. Several plasma-input based...
Semiquantitative PET measures such as SUV ratio (SUVr) have several advantages over quantitative measures, practical applicability and relative computational simplicity. However, SUVr may potentially be affected by changes in blood flow, whereas nondisplaceable binding potential (BP<sub>ND</sub>) are not. For <sup>18</sup>F-flortaucipir PET, the sensitivity of for flow is currently unknown. Therefore, we compared semiquantitative parameters longitudinal scans assessed their vulnerability to...
Off-target [18F]flortaucipir (tau) PET binding in the choroid plexus causes spill-in into nearby hippocampus, which may influence correlation between and measures of cognition. Previously, we showed that partial volume correction (combination Van Cittert iterative deconvolution HYPR denoising; PVC HDH) manually eroding hippocampus resulted a significant decrease spill-in. In this study, compared three different approaches for quantification hippocampal signal using semi-automated technique,...